RESUMO
INTRODUCTION: Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS: Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed. RESULTS: Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation. CONCLUSIONS: Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.
Assuntos
Corticosteroides/administração & dosagem , Síndrome Antifosfolipídica , Hanseníase Multibacilar/imunologia , Talidomida/administração & dosagem , Corticosteroides/efeitos adversos , Adulto , Idoso , Anticorpos Antifosfolipídeos/sangue , Anticorpos Antifosfolipídeos/efeitos dos fármacos , Anticorpos Antifosfolipídeos/genética , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/tratamento farmacológico , Síndrome Antifosfolipídica/genética , Ensaio de Imunoadsorção Enzimática , Fator V/análise , Feminino , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Hanseníase Multibacilar/tratamento farmacológico , Hanseníase Multibacilar/genética , Masculino , Pessoa de Meia-Idade , Mutação , Polimorfismo Genético , Protrombina/análise , Talidomida/efeitos adversos , Tromboembolia Venosa/tratamento farmacológico , beta 2-Glicoproteína I/sangueRESUMO
Abstract INTRODUCTION Corticosteroids and/or thalidomides have been associated with thromboembolism events (TBE) in multibacillary (MB) leprosy. This report aimed to determine genetic and laboratory profiles associated with leprosy and TBE. METHODS Antiphospholipid antibodies (aPL), coagulation-related exams, prothrombin and Leiden's factor V mutations, and ß2-glycoprotein-I (ß2GPI) Val247Leu polymorphism were assessed. RESULTS Six out of seven patients with leprosy were treated with prednisone and/or thalidomide during TBE and presented at least one positive aPL. All patients presented ß2GPI polymorphism, and one showed prothrombin mutation. CONCLUSIONS Corticosteroid or thalidomide adverse effects and aPL and ß2GPI polymorphisms may cause TBE in patients with MB leprosy.